Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction

<p>Abstract</p> <p>Background</p> <p>The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the exist...

Full description

Bibliographic Details
Main Authors: Wang Wen-Ping, Wang Kang-Ning, Gao Qiang, Chen Long-Qi
Format: Article
Language:English
Published: BMC 2012-01-01
Series:World Journal of Surgical Oncology
Subjects:
Epidermal growth factor receptor
Adenocarcinoma of esophagogastric junction
Gene mutation
Single nucleotide polymorphism
Gefitinib
Online Access:http://www.wjso.com/content/10/1/14

Internet

http://www.wjso.com/content/10/1/14

Similar Items